THE
COMPANY
HµREL
Corporation is a development-stage
enterprise based in Beverly Hills, California. HµREL’s
development is proceeding under the aegis of Athena Capital
Partners, LLC, a Los Angeles enterprise sponsorship firm (www.athenacapital.net).
HµREL
is presently inaugurating a Joint Scientific Collaboration
(“JSC”), through which a group of global pharmaceutical
and consumer products firms will collectively provide scientific
guidance and funding as HµREL
carries out a one-year research and development program aimed
at fully validating its technology and readying its first
products for general, commercial release. HµREL
projects its JSC laboratory activities to commence in the
third quarter of 2005.
HµREL’s
first product—a microfluidic circuit that models real-time
protein binding, metabolism, and extraction in the liver—will
comprise the world’s first comprehensive, in vitro
test of first-pass liver bioavailability in humans or other
species. Other HµREL
applications slated for early development include devices
customized for studying various multi-organ toxicities (e.g.,
liver/lung or liver/cardiac), as well as for studying the
integrated mechanisms of absorption and bioavailability of
orally administered compounds.
|
